Digital Pathology Advancing Medicine to the Digital Age – Part of the 25th Annual Molecular Medicine Tri-Conference
February 12-14, 2018 | Moscone South Convention Center | San Francisco, CA
Triconference.com/Digital-Pathology Bristol-Myers Squibb and Genentech to Present on Benefits of Multiplex Immunohistochemistry at CHI’s Digital Pathology Conference in San Francisco
Multiplexes IHC and Image Analysis in Immuno-Oncology Drug Development and Companion Diagnostics
Michael C. Montalto, Ph.D., Executive Director, Translational Medicine, Bristol-Myers Squibb
Conventional immunohistochemistry, multicolor flow cytometry and next-generation sequencing have helped shape our understanding of immuno-oncology based therapeutic approaches. However, these technologies do not provide a comprehensive view of the interactions between tumor and immune cells in the tumor-microenvironment. This talk will explore the role of multiplexed IHC and automated image analysis in I-O drug development, and its potential as a platform for patient stratification and companion diagnostics.
How Digital Pathology and Multiplex IHC Can Help Cancer Patients
Andy Williams, Ph.D., CDx Franchise Leader, Cancer Immune Therapies, Genentech, Inc.
Digital pathology coupled with multiplex IHC provides spatial distribution information: a key advantage over gene expression approaches to capture tumor biology. The current impact and future potential benefits to cancer patients of optimizing this strategy will be optimized in this discussion.Scientific Advisory Board
– Eric F. Glassy, M.D., FCAP, Medical Director, Affiliated Pathologists Medical Group
– Liron Pantanowitz, M.D., Professor, Pathology & Biomedical Informatics, University of Pittsburgh Medical Center, Conference Chairman
– David C. Wilbur, M.D., Professor, Pathology, Massachusetts General HospitalRegister
SAVE up to $400!
Register by December 1
